DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Bevasiranib is an investigational drug.
There have been 5 clinical trials for Bevasiranib. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Macular Degeneration, Edema, and Choroidal Neovascularization. The leading clinical trial sponsors are OPKO Health, Inc. and [disabled in preview].
Recent Clinical Trials for Bevasiranib
|Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)||OPKO Health, Inc.||Phase 3|
|Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD||OPKO Health, Inc.||Phase 3|
|Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema||OPKO Health, Inc.||Phase 2|